Please provide your email address to receive an email when new articles are posted on . A highly purified preparation of ovine hyaluronidase results in a “highly effective” anesthetic block when ...

Please provide your email address to receive an email when new articles are posted on . IRVINE, Calif. — Intravitreous injection of a hyaluronidase product demonstrated a significant reduction in ...

ISTA Pharmaceuticals received a letter from the FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) concerning a journal advertisement for Vitrase, an adjuvant to increase the ...

Bolstering its cash reserves in anticipation of closing a pair of drug development agreements, ISTA Pharmaceuticals Inc. raised $13.3 million in gross proceeds through a common stock offering. The ...

With a new drug application still under review for Vitrase in vitreous hemorrhage, ISTA Pharmaceuticals Inc. is asking the FDA to approve the drug as a spreading agent to facilitate the dispersion and ...

ISTA Pharmaceuticals is touting the pooled data from two Phase III trials of Vitrase for treating vitreous hemorrhage at the back of the eye. The pooled results showed a reduction of vitreous ...

One move forward, another back. Way back. Shares of opthalmic drug maker ISTA Pharmaceuticals (NASDAQ:ISTA) vaulted over 23% in pre-market trading today and continued that trend once the market opened ...